Photo Gallery

Login

Search

News & Updation

  • WJPPS OCTOBER ISSUE PUBLISHED
  • OCTOBER 2017 Issue has been successfully launched on 1 October 2017

  • ICV
  • WJPPS Rank with Index Copernicus Value 52.51 due to high reputation at International Level

  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from 6.041 to 6.647 due to high quality Publication at International Level

  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  

Abstract

SYNERGISTIC EFFECT OF GALANTAMINE CARRIED ON A NOVEL NANO-DRUG DELIVERY SYSTEM ON INDUCED LUNG DISORDERS IN ALZHEIMER’S DISEASE

Walaa Ahmed Moustafa El-Nahrawy*

ABSTRACT

Alzheimer's disease AD, the most common form of dementia, usually presents with lung disorders including lung fibrosis. The aim of the present study was to verify that the curative role of Galantamine (the major therapeutic drug for AD) coated with Ce/Ca-HAp (nano-drug delivery particle) on brain tissue is capable of inducing similar therapeutic capabilities in lung disorders besides its role in AD therapy. Presentation of multiple biomarkers (CYP1A1, CYP2E1, TGF- β1, TAC and TOC) for pulmonary disorders and also brain Markers (5-OH tryptamine, TNF-α & IL-ß1) measured in brain tissuemay induce early detection thus adding to the efficacy of the curative competence. 64 adult female albino Wistar rats (189- 200 gm) were allotted into 4 groups: a) Control: Gonad intact rats (10). b) Alzheimer (Alz): Ovariectomized rats (22) treated orally with AlCl3 (17 mg/kg b.wt) daily for 2 months following one month surgery. c) Alz + Gal rats (16) d) Alz + Gal. + Ce/Ca-HAp rats (16). Results verified marked increases in levels of TNF-α & IL-ß1, TOC, TGF-ß1 while serum TAC and 5-OH tryptamine levels and tissue CYP1A1, CYP2E1 were significantly decreased in AD rats. Histologically, thickening wall of blood vessels and lymphocytes inflammatory infiltration and degenerative alterations were viewed in lung tissue. Patent enhancements were more asserted following nano-therapy than GAL alone. In conclusion, as lung dysfunction highly presents with AD thus early detection using different biomarkers as lung profile (CYP1A1, CYP2E1, TGF-β1) antioxidant and oxidative status (TAC, TOC) and brain markers profile (5-OH tryptamine, TNF-α & IL-ß1) is vital for curative competence.Again as Ce/Ca-HAp nanoparticle presented as coating for GAL drug therapy, more promising ameliorative measures could be achieved.

Keywords: Alzaheimer, lung dysfunction, Galantamine, nanotherapy.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More